1-[(1R,2R)-2-甲基环戊基]乙酮 | 403641-43-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-[(1R,2R)-2-甲基环戊基]乙酮
• 英文名称: (-)-1-(2-methyl-1-cyclopentyl)-ethanone
• 英文别名: (+)-1-acetyl-2-methyl-cyclopentane；trans-1-Acetyl-2-methyl-cyclopentan；Ethanone, 1-(2-methylcyclopentyl)-, trans-；1-[(1R,2R)-2-methylcyclopentyl]ethanone
• CAS: 403641-43-0
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: SIXBTZFYFSHXJI-HTRCEHHLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  toluene-4-sulfonic acid pent-4-enyl ester 在 (4,5-dihydroIMES)Cl₂Ru=CH-o-OiPrC₆H₄ copper(I) trifluoromethanesulfonate benzene 、 2-(diphenylphosphino)-phenyl-L-Tle-L-Tyr(OBut)-Bu 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 18.0h， 生成 1-[(1R,2R)-2-甲基环戊基]乙酮
  参考文献：
  名称：

  Cu催化烷基锌试剂与无环脂肪族烯酮的不对称共轭加成

  摘要：

  报道了铜催化的对映选择性共轭添加到无环脂肪族烯酮。所得的烯醇可以在分子内和分子间进行功能化，从而形成额外的 CC 键。本方法的用途不限于涉及 Et2Zn 的反应；可以使用多种烷基锌。此外，许多必需的底物可以通过催化烯烃交叉复分解轻松获得。

  DOI：

  10.1021/ja0122849

文献信息

• Efficient Cu-Catalyzed Asymmetric Conjugate Additions of Alkylzincs to Trisubstituted Cyclic Enones
  作者：Sylvia J. Degrado、Hirotake Mizutani、Amir H. Hoveyda

  DOI：10.1021/ja021081x

  日期：2002.11.1

  The first examples of efficient catalytic asymmetric conjugate addition (ACA) of alkylzincs to trisubstituted cyclic enones is disclosed. These Cu-catalyzed reactions proceed efficiently with five- and seven-membered ring substrates to afford the desired products in >/=95% ee. Intermediate enolates can be trapped with alkyl halides to generate a quaternary stereogenic center. The requisite chiral ligand

  公开了烷基锌与三取代环烯酮的有效催化不对称共轭加成(ACA)的第一个实例。这些铜催化的反应与五元环和七元环底物一起有效地进行，以 >/= 95% ee 提供所需的产物。中间体烯醇可以被烷基卤化物捕获以生成四元立体中心。必需的手性配体由市售材料制备，并且可以原位使用而无需在商业级 (CuOTf)2.PhMe 存在下进一步纯化。
• Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands
  申请人：Hendrix James A.

  公开号：US20090247509A1

  公开（公告）日：2009-10-01

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其表现出对多巴胺D3受体的选择性结合。另一方面，本发明涉及一种治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，该方法包括向需要此类治疗的患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神疾病、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔斯-德-拉-图雷综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备所述化合物的方法以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。
• Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
  申请人：Hendrix A. James

  公开号：US20070161641A1

  公开（公告）日：2007-07-12

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates is to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其具有选择性地与多巴胺D3受体结合。另一方面，本发明涉及一种治疗中枢神经系统疾病的方法，该疾病与多巴胺D3受体活性有关，包括对患者进行治疗，向患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及所述化合物的制备过程，以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。
• Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
  申请人：Aventis Pharmaceuticals Inc.

  公开号：EP1935887A1

  公开（公告）日：2008-06-25

  The invention relates to heterocyclic substituted carbonyl derivatives of the formula I that display selective binding to dopamine D3 receptors and are useful for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3 receptors.

  本发明涉及式 I 的杂环取代的羰基衍生物 本发明涉及式 I 的杂环取代羰基衍生物，该衍生物与多巴胺 D3 受体具有选择性结合，可用于治疗需要此类治疗的患者中与多巴胺 D3 受体活性相关的中枢神经系统紊乱，包括向受试者施用治疗有效量的所述化合物以缓解此类紊乱。可用这些化合物治疗的中枢神经系统疾病包括精神障碍、药物依赖、药物滥用、运动障碍（如帕金森病、帕金森氏症、神经抑制剂诱发的迟发性运动障碍、吉勒-德拉图雷特综合征和亨廷顿氏病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及本文所述化合物的制备过程以及将这些化合物用作多巴胺 D3 受体成像剂的制备和使用方法。
• SAKAI, TAKASHI;TABATA, HIDEAKI;TAKEDA, AKIRA, J. ORG. CHEM., 1983, 48, N 24, 4618-4621
  作者：SAKAI, TAKASHI、TABATA, HIDEAKI、TAKEDA, AKIRA

  DOI：——

  日期：——